Date: 2015-12-21
Type of information: Nomination
Compound:
Company: SELLAS Life Sciences (Switzerland)
Therapeutic area: Cancer - Oncology - CNS diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 21, 2015, SELLAS Life Sciences Group announced the appointment of Andres A. Gutierrez, M.D., Ph.D., as Chief Medical Officer, effective immediately. Dr. Gutierrez will be responsible for the overall strategic direction and medical oversight of the clinical development of SELLAS’ novel product candidates and will identify further opportunities for development and strategic collaborations. Dr. Gutierrez brings to SELLAS 20 years of experience and expertise in clinical oncology drug development. Prior to joining SELLAS, Dr. Gutierrez served as Medical Director, ECTR Immuno-oncology at Bristol-Myers Squibb, where he oversaw the development of translational and clinical development programs in solid tumors and hematological malignancies. Prior to Bristol-Myers Squibb, Dr. Gutierrez was a Medical Director for several biotechnology companies, including Sunesis Pharmaceuticals; BioMarin Pharmaceutical Inc., and Proteolix, Inc. As Medical Director, he played a key role in the advancement of clinical trials in early- to late-stage development that led to recent drug approvals. He also directed activities to incorporate diagnostics into clinical programs in oncology. Previously, Dr. Gutierrez was Medical Director, Clinical Development & MA at Oculus Innovative Sciences. Prior to Oculus, he served as Director of the Gene Therapy Unit at the National Institutes of Health in Mexico City and as a consultant physician at the Hospital Angeles del Pedregal. Dr. Gutierrez received his M.D. and Ph.D. from the National University of Mexico, with a specialty in internal medicine and a fellowship in clinical oncology at the Hammersmith Hospital (RPMS) in London, UK.
Financial terms:
Latest news:
